University of Aberdeen logo

AURA - Aberdeen University Research Archive

 

In-vivo evidence that high mobility group box 1 exerts deleterious effects in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model and Parkinson's disease which can be attenuated by glycyrrhizin

Simple item page
dc.contributor.authorSantoro, Matteo
dc.contributor.authorMaetzler, Walter
dc.contributor.authorStathakos, Petros
dc.contributor.authorMartin, Heather L.
dc.contributor.authorHobert, Markus A.
dc.contributor.authorRattray, Tim W.
dc.contributor.authorGasser, Thomas
dc.contributor.authorForrester, John V.
dc.contributor.authorBerg, Daniela
dc.contributor.authorTracey, Kevin J.
dc.contributor.authorRiedel, Gernot
dc.contributor.authorTeismann, Peter
dc.contributor.institutionUniversity of Aberdeen.Medicine, Medical Sciences & Nutritionen
dc.contributor.institutionUniversity of Aberdeen.Medical Sciencesen
dc.contributor.institutionUniversity of Aberdeen.Applied Medicineen
dc.date.accessioned2016-03-29T15:00:05Z
dc.date.available2016-03-29T15:00:05Z
dc.date.issued2016-07
dc.descriptionAcknowledgements Samples were obtained from the Neuro Biobank of the University of Tuebingen, Germany (http://www.hih-tuebingen.de/nd/biobank/for-researchers/). This biobank is supported by the Hertie Institute and the DZNE. We are grateful to the staff of the Medical Research Facility for their help with the animal care. We thank Dr. Kinnari Sathe for her help with the experiments. We thank Claire A. Walker for assisting with western blot analysis. This study was supported by: Tenovus Scotland, Parkinson's Disease Foundation, Royal Society 2006/R1, NHS Endowment 14-42, and Wellcome Trust WT080782MF.en
dc.description.statusPeer revieweden
dc.format.extent10
dc.format.extent2990444
dc.identifier62868043
dc.identifier81030cfb-7168-46c7-a10c-1ba70c51b88c
dc.identifier84962520475
dc.identifier.citationSantoro, M, Maetzler, W, Stathakos, P, Martin, H L, Hobert, M A, Rattray, T W, Gasser, T, Forrester, J V, Berg, D, Tracey, K J, Riedel, G & Teismann, P 2016, 'In-vivo evidence that high mobility group box 1 exerts deleterious effects in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model and Parkinson's disease which can be attenuated by glycyrrhizin', Neurobiology of Disease, vol. 91, pp. 59-68. https://doi.org/10.1016/j.nbd.2016.02.018en
dc.identifier.doi10.1016/j.nbd.2016.02.018
dc.identifier.issn0969-9961
dc.identifier.urihttp://hdl.handle.net/2164/5783
dc.identifier.vol91en
dc.language.isoeng
dc.relation.ispartofNeurobiology of Diseaseen
dc.subjectSDG 3 - Good Health and Well-beingen
dc.subjectParkinson's diseaseen
dc.subjectMPTPen
dc.subjectHigh-mobility group box 1en
dc.subjectreceptor for advanced glycation endproductsen
dc.subjectRC0321 Neuroscience. Biological psychiatry. Neuropsychiatryen
dc.subjectWellcome Trusten
dc.subjectWT080782MFen
dc.subject.lccRC0321en
dc.titleIn-vivo evidence that high mobility group box 1 exerts deleterious effects in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model and Parkinson's disease which can be attenuated by glycyrrhizinen
dc.typeJournal articleen

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
1_s2.0_S0969996116300407_main.pdf
Size:
2.85 MB
Format:
Adobe Portable Document Format
Download

License bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
8.29 KB
Format:
Plain Text
Description:
Download

Collections

All research
Applied Medicine research
Medical Sciences research
University Office research